Eliyahu Sharon Kalif Teva Pharmaceutical Industries LTD (TEVA) insider trading activity

Eliyahu Sharon Kalif is EVP, Chief Financial Officer of TEVA PHARMACEUTICAL INDUSTRIES LTD. Currently has a direct ownership of 459,063 shares of TEVA, which is worth approximately $7.46 Million. The most recent transaction as insider was on Mar 05, 2025, when has been sold 21,390 shares (Ordinary Shares) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 459K

125.37% 3M change

125.37% 12M change

Total Value Held $7.46 Million

Eliyahu Sharon Kalif Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 05 2025	BUY Exercise of conversion of derivative security	-	21,390 Added 4.45%	459,063 Ordinary Shares
Mar 04 2025	BUY Exercise of conversion of derivative security	-	239,932 Added 35.41%	437,673 Ordinary Shares
Mar 03 2025	BUY Exercise of conversion of derivative security	-	49,800 Added 20.12%	197,741 Ordinary Shares
Feb 28 2025	SELL Open market or private sale	$903,707 $16.21 p/Share	55,750 Reduced 27.37%	147,941 Ordinary Shares
Mar 06 2024	SELL Open market or private sale	$1,048,476 $13.52 p/Share	77,550 Reduced 27.57%	203,691 Ordinary Shares
Mar 05 2024	BUY Exercise of conversion of derivative security	-	73,707 Added 20.77%	281,241 Ordinary Shares
Mar 04 2024	BUY Exercise of conversion of derivative security	-	33,512 Added 13.9%	207,534 Ordinary Shares
Mar 03 2024	BUY Exercise of conversion of derivative security	-	49,800 Added 22.25%	174,022 Ordinary Shares
Feb 28 2024	BUY Exercise of conversion of derivative security	-	18,430 Added 12.92%	124,222 Ordinary Shares
Feb 13 2024	BUY Exercise of conversion of derivative security	-	6,630 Added 5.9%	105,792 Ordinary Shares
Aug 07 2023	SELL Open market or private sale	$341,766 $9.73 p/Share	35,125 Reduced 26.16%	99,162 Ordinary Shares
Mar 05 2023	BUY Exercise of conversion of derivative security	-	21,387 Added 13.74%	134,287 Ordinary Shares
Mar 04 2023	BUY Exercise of conversion of derivative security	-	33,512 Added 22.89%	112,900 Ordinary Shares
Feb 28 2023	BUY Exercise of conversion of derivative security	-	63,383 Added 44.39%	79,388 Ordinary Shares
Feb 13 2023	BUY Exercise of conversion of derivative security	-	6,629 Added 29.29%	16,005 Ordinary Shares
Aug 22 2022	SELL Open market or private sale	$558,885 $10.07 p/Share	55,500 Reduced 85.55%	9,376 Ordinary Shares
Mar 05 2022	BUY Exercise of conversion of derivative security	-	21,387 Added 24.79%	64,876 Ordinary Shares
Feb 28 2022	BUY Exercise of conversion of derivative security	-	18,430 Added 29.76%	43,489 Ordinary Shares
Feb 13 2022	BUY Exercise of conversion of derivative security	-	6,629 Added 20.92%	25,059 Ordinary Shares
Feb 28 2021	BUY Exercise of conversion of derivative security	-	18,430 Added 50.0%	18,430 Ordinary Shares

ESK

Eliyahu Sharon Kalif

EVP, Chief Financial Officer

Tel Aviv, L3

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TEVA shares.

Notify only if

Value

Insider Trading

Get notified when an Teva Pharmaceutical Industries LTD insider buys or sells TEVA shares.

Notify only if

Operation

Value

Type

News

Receive news related to TEVA PHARMACEUTICAL INDUSTRIES LTD

Track Activities on TEVA

Account